About ADMA Biologics

ADMA Biologics, Inc. (Nasdaq: ADMA), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to the manufacturing, developing, and commercializing of specialty biologic products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for certain infections. Our devotion to these underserved populations fuels us, and our hands-on approach to production and development sets us apart.

With three FDA-approved products, including ASCENIV™ (Immune Globulin Intravenous, Human–slra), BIVIGAM® (Immune Globulin Intravenous, Human), and Nabi-HB® (Hepatitis B Immune Globulin, Human), ADMA’s mission is to continue to commercialize specialty biologic products, targeted to specific patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations.